Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Aspira Pathlab & Diagnostics's Days Inventory for the
three
months ended in Jun. 2026 was 51.31.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Aspira Pathlab & Diagnostics's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.11.
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Aspira Pathlab & Diagnostics's Days Inventory for the
three
months ended in Jun. 2026 is calculated as:
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Aspira Pathlab & Diagnostics's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.
Aspira Pathlab & Diagnostics Inventory Turnover Related Terms
Aspira Pathlab & Diagnostics Inventory Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Pathlab & Diagnostics (BOM:540788) has a Inventory Turnover of 1.78 as of Jun. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Aspira Pathlab & Diagnostics and its competitors.
Is Aspira Pathlab & Diagnostics' Inventory Turnover too high?
Aspira Pathlab & Diagnostics' current Inventory Turnover is 1.78. Overall, Aspira Pathlab & Diagnostics has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Pathlab & Diagnostics' Inventory Turnover compare to TMO and DHR?
Aspira Pathlab & Diagnostics' Inventory Turnover of 1.78 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Medical Diagnostics & Research company?
A good Inventory Turnover depends on the Medical Diagnostics & Research industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Aspira Pathlab & Diagnostics and its competitors. Aspira Pathlab & Diagnostics's current Inventory Turnover is 1.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Pathlab & Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics (BOM:540788) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹71.16, compared to a current price of ₹91.85 — trading 29.1% above its estimated fair value. The current Inventory Turnover is 1.78. Aspira Pathlab & Diagnostics' overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For Aspira Pathlab & Diagnostics (BOM:540788), the current Inventory Turnover is 1.78 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Pathlab & Diagnostics (BOM:540788) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics stock appears to be overvalued.
The current stock price of ₹91.85 is trading 29.1% above its estimated GF Value™ of ₹71.16.
GuruFocus considers Aspira Pathlab & Diagnostics to be Modestly Overvalued.
Key valuation signals for BOM:540788:
Inventory Turnover: 1.78
GF Value™: ₹71.16 vs. price of ₹91.85 (29.1% above fair value)
No single metric tells the full story. See the BOM:540788 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Pathlab & Diagnostics Ltd is mainly engaged in pathology and related healthcare services. It operates laboratories that conduct a wide range of pathological investigations across branches such as biochemistry, hematology, histopathology, microbiology, immunochemistry, immunology, virology, cytology, and other pathological and radiological tests. The services offered include pathology tests, sonography, X-rays, and radiology. The company also provides various health packages like gynecology profiles, anemia profiles, monsoon profiles, coagulation tests, cancer screening packages, newborn screening and IEM panels, orthopedic profiles, allergy panels, and cardiac profiles. These comprehensive diagnostic services assist in disease diagnosis.
51GF Score
Get the complete analysis for BOM:540788
Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540788 has been successfully added to your 
